321 related articles for article (PubMed ID: 27040343)
41. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
42. Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease.
Chen G; Ni Y; Nagata N; Xu L; Ota T
Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27563875
[TBL] [Abstract][Full Text] [Related]
43. Non-alcoholic fatty liver disease in HIV infection associated with altered hepatic fatty acid composition.
Arendt BM; Mohammed SS; Ma DW; Aghdassi E; Salit IE; Wong DK; Guindi M; Sherman M; Heathcote EJ; Allard JP
Curr HIV Res; 2011 Mar; 9(2):128-35. PubMed ID: 21434863
[TBL] [Abstract][Full Text] [Related]
44. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
[TBL] [Abstract][Full Text] [Related]
45. Omega-3 fatty acids as a treatment for non-alcoholic fatty liver disease in children: A systematic review and meta-analysis of randomized controlled trials.
Chen LH; Wang YF; Xu QH; Chen SS
Clin Nutr; 2018 Apr; 37(2):516-521. PubMed ID: 28040302
[TBL] [Abstract][Full Text] [Related]
46. Omega-3 polyunsaturated fatty acid and ursodeoxycholic acid have an additive effect in attenuating diet-induced nonalcoholic steatohepatitis in mice.
Kim JK; Lee KS; Lee DK; Lee SY; Chang HY; Choi J; Lee JI
Exp Mol Med; 2014 Dec; 46(12):e127. PubMed ID: 25523099
[TBL] [Abstract][Full Text] [Related]
47. Nonalcoholic fatty liver disease: from lipid profile to treatment.
Miura K; Ohnishi H
Clin J Gastroenterol; 2012 Oct; 5(5):313-21. PubMed ID: 26181068
[TBL] [Abstract][Full Text] [Related]
48. The importance of the long-chain polyunsaturated fatty acid n-6/n-3 ratio in development of non-alcoholic fatty liver associated with obesity.
Valenzuela R; Videla LA
Food Funct; 2011 Nov; 2(11):644-8. PubMed ID: 22008843
[TBL] [Abstract][Full Text] [Related]
49. Soybean Oil-Derived Poly-Unsaturated Fatty Acids Enhance Liver Damage in NAFLD Induced by Dietary Cholesterol.
Henkel J; Alfine E; Saín J; Jöhrens K; Weber D; Castro JP; König J; Stuhlmann C; Vahrenbrink M; Jonas W; Kleinridders A; Püschel GP
Nutrients; 2018 Sep; 10(9):. PubMed ID: 30231595
[TBL] [Abstract][Full Text] [Related]
50. Variation in the Plasma Levels of Polyunsaturated Fatty Acids in Control vis-à-vis Nonalcoholic Fatty Liver Disease Subjects and Its Possible Association with Gut Microbiome.
Vernekar M; Singhal R; Joshi K; Amarapurkar D
Metab Syndr Relat Disord; 2018 Sep; 16(7):329-335. PubMed ID: 29873593
[TBL] [Abstract][Full Text] [Related]
51. Role of bioactive fatty acids in nonalcoholic fatty liver disease.
Juárez-Hernández E; Chávez-Tapia NC; Uribe M; Barbero-Becerra VJ
Nutr J; 2016 Aug; 15(1):72. PubMed ID: 27485440
[TBL] [Abstract][Full Text] [Related]
52. Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis.
Alonso C; Fernández-Ramos D; Varela-Rey M; Martínez-Arranz I; Navasa N; Van Liempd SM; Lavín Trueba JL; Mayo R; Ilisso CP; de Juan VG; Iruarrizaga-Lejarreta M; delaCruz-Villar L; Mincholé I; Robinson A; Crespo J; Martín-Duce A; Romero-Gómez M; Sann H; Platon J; Van Eyk J; Aspichueta P; Noureddin M; Falcón-Pérez JM; Anguita J; Aransay AM; Martínez-Chantar ML; Lu SC; Mato JM
Gastroenterology; 2017 May; 152(6):1449-1461.e7. PubMed ID: 28132890
[TBL] [Abstract][Full Text] [Related]
53. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.
Pierantonelli I; Svegliati-Baroni G
Transplantation; 2019 Jan; 103(1):e1-e13. PubMed ID: 30300287
[TBL] [Abstract][Full Text] [Related]
54. Efficacy of the Omega-3 Index in predicting non-alcoholic fatty liver disease in overweight and obese adults: a pilot study.
Parker HM; O'Connor HT; Keating SE; Cohn JS; Garg ML; Caterson ID; George J; Johnson NA
Br J Nutr; 2015 Sep; 114(5):780-7. PubMed ID: 26202539
[TBL] [Abstract][Full Text] [Related]
55. Effects of a 6-month dietary-induced weight loss on erythrocyte membrane omega-3 fatty acids and hepatic status of subjects with nonalcoholic fatty liver disease: The Fatty Liver in Obesity study.
Marin-Alejandre BA; Abete I; Monreal JI; Elorz M; Benito-Boillos A; Herrero JI; Navarro-Blasco I; Tur JA; Bandarra NM; Zulet MA; Martinez JA
J Clin Lipidol; 2020; 14(6):837-849.e2. PubMed ID: 32962964
[TBL] [Abstract][Full Text] [Related]
56. Chronic consumption of fructose in combination with trans fatty acids but not with saturated fatty acids induces nonalcoholic steatohepatitis with fibrosis in rats.
Jeyapal S; Putcha UK; Mullapudi VS; Ghosh S; Sakamuri A; Kona SR; Vadakattu SS; Madakasira C; Ibrahim A
Eur J Nutr; 2018 Sep; 57(6):2171-2187. PubMed ID: 28676973
[TBL] [Abstract][Full Text] [Related]
57. Hepatic Alanine Differentiates Nonalcoholic Steatohepatitis From Simple Steatosis in Humans and Mice: A Proton MR Spectroscopy Study With Long Echo Time.
Kim TH; Jun HY; Kim KJ; Lee YH; Lee MS; Choi KH; Yun KJ; Jeong YY; Jun CH; Cho EY; Yoon KH
J Magn Reson Imaging; 2017 Nov; 46(5):1298-1310. PubMed ID: 28225569
[TBL] [Abstract][Full Text] [Related]
58. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
Zhou JH; Cai JJ; She ZG; Li HL
World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
[TBL] [Abstract][Full Text] [Related]
59. Impact of the Co-Administration of N-3 Fatty Acids and Olive Oil Components in Preclinical Nonalcoholic Fatty Liver Disease Models: A Mechanistic View.
Valenzuela R; Videla LA
Nutrients; 2020 Feb; 12(2):. PubMed ID: 32075238
[TBL] [Abstract][Full Text] [Related]
60. Nonalcoholic Fatty Liver Disease: Pathophysiology and Management.
Carr RM; Oranu A; Khungar V
Gastroenterol Clin North Am; 2016 Dec; 45(4):639-652. PubMed ID: 27837778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
